Cormorant Asset Management, LP Clearside Biomedical, Inc. Transaction History

Cormorant Asset Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$1.0 - $6.12 $400,000 - $2.45 Million	-400,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$6.03 - $11.24 $4.82 Million - $8.99 Million	-800,000 Reduced 66.67%	400,000 $2.46 Million
Q2 2018 Aug 14, 2018	SELL	$8.91 - $14.54 $6.07 Million - $9.9 Million	-680,880 Reduced 36.2%	1,200,000 $12.8 Million
Q1 2018 May 15, 2018	SELL	$5.57 - $14.28 $334,200 - $856,800	-60,000 Reduced 3.09%	1,880,880 $20.2 Million
Q3 2017 Nov 14, 2017	BUY	$6.73 - $8.74 $13.1 Million - $17 Million	1,940,880	1,940,880 $17 Million

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $52.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.